Adverse Events & Existing Treatment Options for Dry Eye Disease

EP: 1.Overview of Dry Eye Disease (DED) Causes and Treatments

Now Viewing

EP: 2.Adverse Events & Existing Treatment Options for Dry Eye Disease

EP: 3.Navigating Different Subtypes of Dry Eye Disease

EP: 4.Assessing Efficacy of Treatment Through Patient-Reported Outcomes

EP: 5.Updating Formularies: Considerations for Dry Eye Disease

EP: 6.Assessing the Economic Burden of Under Diagnosed Dry Eye Disease

EP: 7.Identifying Key Socioeconomic Burdens Associated with Dry Eye Disease

EP: 8.Resource Allocation in the Treatment of Dry Eye Disease

EP: 9.Quality of Life & Patient Reported Outcomes in Dry Eye Disease

EP: 10.Annual Health Care Costs of Managing Dry Eye Disease

EP: 11.Novel Treatments Targeting Symptoms & Causes of Dry Eye Disease

EP: 12.Evaluating Treatment Outcomes in Dry Eye Disease

EP: 13.Evaluating Economic Impact of Emerging Therapies for Dry Eye Disease

EP: 14.Concluding Thoughts on the Treatment of Dry Eye Disease

This is a video synopsis/summary of a Stakeholder Summit involving:

Ryan Haumschild, PharmD, MS, MBA; Jai G. Parekh, MD, MBA; and Alexander Kabiri, OD.

Kabiri discusses limitations of existing dry eye disease (DED) treatments. Patients may not understand what constitutes good DED outcomes compared with temporary relief with over-the-counter drops. Prescription immunomodulators can take weeks to months for noticeable improvement, may cause more installation discomfort than patients expect based on past experience, and have a different timeline for perceived benefit. This can lead some patients to discontinue treatment prematurely.

Parekh reviews common adverse events with DED treatments such as burning, stinging, and taste issues with cyclosporine ophthalmic emulsion (Restasis) and its generics. Lack of familiarity with adverse effect profiles with new generics entering the market poses an additional challenge. It is important to educate patients up front on potential adverse events so that they understand what to expect, remain compliant, and follow up regularly to facilitate adherence. This comprehensive patient education around a predictable, tolerated treatment is key.

Kabiri notes unpredictability in ocular surface comfort and distribution with compounded topical cyclosporine formulations. Inconsistency between formulations can negatively impact patient experience, treatment adherence, provider confidence in managing DED, and outcomes.

Video synopsis is AI-generated and reviewed by AJMCÒ editorial staff.